VEGFA and neoplasm: Preclinical data showed that the normalization process produced by VEGF pathway inhibitors occurred in a dose-dependent manner.16 High doses of antiangiogenic agents resulted in a short vessel normalization window.28 In contrast, low doses of antiangiogenic agents may prolong vessel normalization and thereby reduce tumor hypoxia and enhance the infiltration of immune cells into tumors.16 In the current study, 19 of 23 patients who received more than six cycles of treatment received one half of the starting dose of apatinib (Data Supplement).